Provided by Tiger Trade Technology Pte. Ltd.

Collegium Pharmaceutical

22.02
+0.18000.82%
Post-market: 22.020.00000.00%19:30 EDT
Volume:694.06K
Turnover:15.29M
Market Cap:716.87M
PE:17.34
High:22.38
Open:21.97
Low:21.64
Close:21.84
52wk High:50.79
52wk Low:21.43
Shares:32.56M
Float Shares:31.37M
Volume Ratio:0.86
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.27
EPS(LYR):1.73
ROE:17.61%
ROA:5.75%
PB:2.30
PE(LYR):12.73

Loading ...

Collegium Pharmaceutical Rocked by Eye-Catching Insider Stock Move

TIPRANKS
·
May 14

Collegium Pharma director Garen G. Bohlin disposes 8,700 shares for $323,493.23

Reuters
·
May 14

Barclays Keeps Their Buy Rating on Collegium Pharmaceutical (COLL)

TIPRANKS
·
May 13

BRIEF-Collegium Completes Acquisition Of Azstarys® From Corium Therapeutics

Reuters
·
May 12

Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition

TIPRANKS
·
May 12

Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance

MT Newswires Live
·
May 12

Collegium raises 2026 net product revenue outlook to $865-$895 million

Reuters
·
May 12

Collegium Completes Acquisition of Azstarys® From Corium Therapeutics

THOMSON REUTERS
·
May 12

Press Release: Collegium Completes Acquisition of AZSTARYS(R) from Corium Therapeutics

Dow Jones
·
May 12

Stock Track | Collegium Pharmaceutical Soars 8.46% in Pre-market on Strong Q1 Results and Guidance Reaffirmation

Stock Track
·
May 07

Collegium Pharmaceutical reports Q1 EPS $1.76, consensus $1.52

TIPRANKS
·
May 07

GUIDANCE: (COLL) Collegium Pharmaceutical Expects 2026 Net Product Revenue Range $805M - $825M

MT Newswires Live
·
May 07

Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate

Benzinga Earnings
·
May 07

Collegium Pharmaceutical Q1 Adjusted EPS USD 1.76 VS. Ibes Estimate USD 1.59

THOMSON REUTERS
·
May 07

Collegium Pharmaceutical Inc - Reaffirmed Full-Year 2026 Guidance for Current Business

THOMSON REUTERS
·
May 07

Collegium Pharmaceutical Inc - Ended Q1'26 With Cash, Cash Equivalents and Marketable Securities of $421.8 Mln

THOMSON REUTERS
·
May 07

Press Release: Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

Dow Jones
·
May 07

Earning Preview: Collegium Pharmaceutical Q1 revenue is expected to increase by 8.52%, and institutional views are bullish

Earnings Agent
·
May 01

Collegium Pharmaceutical to report first-quarter financial results, host earnings call

Reuters
·
Apr 23

Analysts Conflicted on These Healthcare Names: Sanofi (SNY), BrightSpring Health Services, Inc. (BTSG) and Collegium Pharmaceutical (COLL)

TIPRANKS
·
Apr 23